Group 1 - The core point of the announcement is that Anselme Limited, as the buyer, has entered into a conditional sale agreement with seller Li Jingyang to acquire 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share [1] - Following the completion of the transaction, the buyer will directly and beneficially own 121 million shares, which is about 24.13% of the total issued share capital of the company [1] - After the completion of the transaction, the buyer, Dr. Zhou and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1][2] Group 2 - The offer price of HKD 0.126 per share represents a discount of approximately 68.10% compared to the closing price of HKD 0.395 per share on the date of the announcement [1] - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [3]
华康生物医学(08622)获Anselme Limited收购27.71%股份及折让约68.1...